Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient

• Published in: American journal of obstetrics & gynecology MFM 2020-11, Vol.2 (4), p.100224-100224, Article 100224
• Main Authors: Lat, Tasnim I., Patel, Chhaya D., Ehrig, Jessica C., Moslander, Conner, Sanchez, Juan F.
• Format: Article
• Language: English
• Subjects: Anticoagulants - pharmacology; anticoagulation; Antiviral Agents - pharmacology; chloroquine; Clinical; convalescent plasma; corticosteroids; COVID-19 - diagnosis; COVID-19 - drug therapy; COVID-19 - therapy; Female; Humans; hydroxychloroquine; Immunization, Passive - methods; interleukin-6 inhibitors; lopinavir-ritonavir; Patient Selection; Pregnancy; Pregnancy Complications, Infectious - diagnosis; Pregnancy Complications, Infectious - drug therapy; remdesivir; SARS-CoV-2 - drug effects; severe acute respiratory syndrome coronavirus 2
• ISSN: 2589-9333; 2589-9333
• DOI: 10.1016/j.ajogmf.2020.100224

The severe acute respiratory syndrome coronavirus 2 pandemic has resulted in the development of various therapeutics to treat and prevent major complications related to the virus; pregnant patients are vulnerable to acquiring severe acute respiratory syndrome coronavirus 2 because of frequent contact with the healthcare setting. Despite the publication of a plethora of case series and randomized control trials of severe acute respiratory syndrome coronavirus 2 therapeutics, few have addressed treatment in the pregnant population. To date, there has been no published review of therapeutic options in the treatment of pregnant patients with severe acute respiratory syndrome coronavirus 2 infection. Here, we provide a review of available treatments for severe acute respiratory syndrome coronavirus 2, various trials with inclusion and exclusion of the pregnant patients, and potential side effects of each treatment in the pregnant patient.